Why the study?
Does discontinuing anticoagulant therapy perioperatively prevent thromboembolic complications and hemostasis difficulties in patients with cardiac valve prostheses undergoing noncardiac surgery?
Does discontinuing anticoagulant therapy perioperatively prevent thromboembolic complications and hemostasis difficulties in patients with cardiac valve prostheses undergoing noncardiac surgery?
Answers are grounded in this paper and cite their sources.
Discontinuing anticoagulation for a few days perioperatively in patients with mechanical heart valves undergoing noncardiac surgery carries minimal in-hospital thromboembolic risk.
Between 1962 and 1975, a total of 159 patients with previously implanted man-made cardiac valve prostheses underwent 180 subsequent noncardiac operations at Mayo Clinic. All of these patients were receiving anticoagulants. The overall incidence of their documentable thromboembolic complications was approximately 10%. None of the postoperative complications occurred while the patient was in hospital, with the earliest such complication seen two years later. Patients receiving anticoagulants on a long-term basis did, however, have a 13% incidence of various difficulties with hemostasis during and following the later operations. We conclude that there is minimal risk to patients with cardiac valve prostheses who are receiving anticoagulants when the drug regimen is stopped for one to three days preoperatively and one to seven days postoperatively. ( JAMA 239:738-739, 1978)
No takes yet. Share an insight, caveat, or question.
Tinker et al. (1978) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: